2019
1249-P: Development and Validation of a Measure for Appropriateness of Glucose-Lowering Therapy
MCCOY R, LIPSKA K, HOUTEN H, SHAH N. 1249-P: Development and Validation of a Measure for Appropriateness of Glucose-Lowering Therapy. Diabetes 2019, 68 DOI: 10.2337/db19-1249-p.Peer-Reviewed Original ResearchGlucose lowering therapiesOptimal therapeutic regimensGlucose lowering medicationsDiabetes quality indicatorsNational InstituteMedicare Advantage enrolleesPatient-centered approachHigh-complexity patientsPerson/yearComorbidity burdenHospitalization visitsTreatment burdenHypoglycemia riskKidney diseaseTherapeutic regimensNational cohortNumber/typeClinical complexityPatientsMedicaid ServicesOptumLabsDiabetesTherapyVisitsAmerican Association
2018
Cost-Related Insulin Underuse Is Common and Associated with Poor Glycemic Control
HERKERT D, VIJAYAKUMAR P, LUO J, SCHWARTZ J, RABIN T, DEFILIPPO E, LIPSKA K. Cost-Related Insulin Underuse Is Common and Associated with Poor Glycemic Control. Diabetes 2018, 67 DOI: 10.2337/db18-2-or.Peer-Reviewed Original ResearchCost-related underusePoor glycemic controlGlycemic controlDiabetes CenterCross-sectional surveyDM durationPrimary outcomeLess insulinHigher oddsPatientsSmall dosesDrug coverageLogistic regressionInsulinUnderuseMedicaid ServicesEssential medicinesNational InstituteInsulin 3Lower income levelsInsulin 5AgePositive responseHealthUrgent need